Added to chemotherapy, this drug doubles lung cancer survival
from Medical News Today
A new study suggests that combining chemotherapy with a drug that boosts the immune system may help individuals who have a particularly aggressive form of lung cancer to live longer without the disease progressing. The new phase III clinical trial demonstrated that adding the immunotherapy drug pembrolizumab to chemotherapy doubled survival in people with metastatic nonsquamous nonsmall cell lung cancer and no mutations in the epidermal growth factor receptor gene or the anaplastic lymphoma kinase gene.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063